Michael Brewster
Overview
Explore the profile of Michael Brewster including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
262
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gibiansky E, Gibiansky L, Buchheit V, Frey N, Brewster M, Fingerle-Rowson G, et al.
Br J Clin Pharmacol
. 2019 May;
85(9):1935-1945.
PMID: 31050355
Aims: Rituximab is standard care in a number of lymphoma subtypes, including follicular lymphoma (FL), although many patients are resistant to rituximab, or develop resistance with repeated treatment, and a...
2.
Davies A, Merli F, Mihaljevic B, Mercadal S, Siritanaratkul N, Solal-Celigny P, et al.
Lancet Haematol
. 2017 May;
4(6):e272-e282.
PMID: 28476440
Background: Intravenous rituximab is the standard of care in B-cell non-Hodgkin lymphoma, and is administered over 1·5-6 h. A subcutaneous formulation could reduce patients' treatment burden and improve resource utilisation...
3.
Zhai J, Qin Y, Zhu J, Song Y, Shen Z, Du X, et al.
Br J Clin Pharmacol
. 2017 Jan;
83(7):1446-1456.
PMID: 28072473
Aim: The Phase Ib GERSHWIN study (NCT01680991) assessed the pharmacokinetic (PK) profile of obinutuzumab following multiple intravenous (i.v.) doses to Chinese patients with B-cell lymphomas, and compared findings with previous...
4.
Menke-van der Houven van Oordt C, Gomez-Roca C, van Herpen C, Coveler A, Mahalingam D, Verheul H, et al.
Oncotarget
. 2016 Aug;
7(48):80046-80058.
PMID: 27507056
Transmembrane glycoprotein CD44 is overexpressed in various malignancies. Interactions between CD44 and hyaluronic acid are associated with poor prognosis, making CD44 an attractive therapeutic target. We report results from a...
5.
Vey N, Delaunay J, Martinelli G, Fiedler W, Raffoux E, Prebet T, et al.
Oncotarget
. 2016 Apr;
7(22):32532-42.
PMID: 27081038
RG7356, a recombinant anti-CD44 immunoglobulin G1 humanized monoclonal antibody, inhibits cell adhesion and has been associated with macrophage activation in preclinical models. We report results of a phase I dose-escalation...
6.
Assouline S, Buccheri V, Delmer A, Gaidano G, Trneny M, Berthillon N, et al.
Lancet Haematol
. 2016 Mar;
3(3):e128-38.
PMID: 26947201
Background: Part one of the two-part SAWYER study predicted that subcutaneous rituximab 1600 mg would achieve trough serum concentrations that were non-inferior to those achieved with intravenous rituximab 500 mg/m(2)...
7.
Assouline S, Buccheri V, Delmer A, Gaidano G, McIntyre C, Brewster M, et al.
Br J Clin Pharmacol
. 2015 Apr;
80(5):1001-9.
PMID: 25900065
Aims: The aim of the phase Ib, two part SAWYER study (BO25341; NCT01292603) was to investigate the pharmacokinetics and safety of subcutaneous (s.c.) rituximab compared with intravenous (i.v.) rituximab, both...
8.
Dakhil S, Hermann R, Schreeder M, Gregory S, Monte M, Windsor K, et al.
Leuk Lymphoma
. 2014 Jan;
55(10):2335-40.
PMID: 24471908
This phase III, multicenter, single-arm trial investigated the impact of 90 min rituximab infusions on infusion-related reactions (IRRs) in patients with untreated diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma...
9.
Garg A, Li J, Clark E, Knott A, Carrothers T, Marier J, et al.
Cancer Chemother Pharmacol
. 2013 Sep;
72(5):1133-41.
PMID: 23999693
Purpose: The phase III trial of pertuzumab plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus docetaxel for first-line treatment of HER2-positive metastatic breast cancer included a substudy to determine...
10.
Leyland-Jones B, Colomer R, Trudeau M, Wardley A, Latreille J, Cameron D, et al.
J Clin Oncol
. 2009 Dec;
28(6):960-6.
PMID: 20026806
PURPOSE Pharmacokinetics (PKs) and safety results from phase II/III trials suggest that, if high trastuzumab serum concentrations are reached early during treatment for human epidermal growth factor receptor 2 (HER2)-positive...